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North CarolinaChronic hepatitis C virus infection is well-recognized as a
common blood-borne infection with global public health
impact affecting 3 to 5 million persons in the United States
and more than 170 million persons worldwide. Chronic
hepatitis C virus infection is associated with significant
morbidity and mortality due to complications of liver
cirrhosis and hepatocellular carcinoma. Current therapies
with all-oral direct-acting antiviral agents are associated
with high rates of sustained virologic response (SVR),
generally exceeding 90%. SVR is associated with a reduced
risk of liver cirrhosis, hepatic decompensation, need for
liver transplantation, and both liver-related and all-cause
mortality. However, a subset of patients who achieve SVR
will remain at long-term risk for progression to cirrhosis,
liver failure, hepatocellular carcinoma, and liver-related
mortality. Limited evidence is available to guide clinicians
on which post-SVR patients should be monitored vs dis-
charged, how to monitor and with which tests, how
frequently should monitoring occur, and for how long. In
this clinical practice update, available evidence and expert
opinion are used to generate best practice recommenda-
tions on the care of patients with chronic hepatitis C virus
who have achieved SVR.Keywords: Hepatitis C; Antiviral Therapy; Direct-Acting
Antiviral Therapy; Sustained Virologic Response; Liver Fibrosis;
Laboratory Monitoring; Hepatocellular Carcinoma.
he battle against hepatitis C virus (HCV) has culmi-Abbreviations used in this paper: AFP, a-fetoprotein; CI, confidence
interval; DAA, direct-acting antiviral; HCC, hepatocellular carcinoma; HCV,
hepatitis C virus; IFN, interferon; MRI, magnetic resonance imaging; SVR,
sustained virologic response; SVR12, sustained virologic response 12
weeks after completion of treatment; TE, transient elastography.
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http://dx.doi.org/10.1053/j.gastro.2017.03.018Tnated in remarkably high rates of sustained virologic
response (SVR) conferred by 6 currently approved inter-
feron (IFN)-free direct-acting antiviral (DAA) regimens
against genotypes 16 HCV.16 In the many countries where
these regimens are available, the use of IFN has essentially
ceased. Follow-up studies and cumulative experience have
affirmed that, as with earlier IFN-based therapy, SVR is
tantamount to virologic cure. Fewer than 1% of patients
relapse after SVR, defined during the years of IFN therapy as
HCV RNA undetectability 24 weeks, and more recently as 12
weeks, after completion of treatment (SVR12).713
With the increasingly frequent opportunity to celebrate
virologic cure with patients comes the corresponding needto advise them about whether, when, and for how long
ongoing care for liver disease is needed. Therefore, it is
critical to identify the ongoing risks for the individual pa-
tient and the measures needed to mitigate those risks.
Numerous studies in patients cured of HCV by IFN-based
therapy have demonstrated reductions in all-cause mortal-
ity, liver-related mortality, need for liver transplantation,
variceal bleeding, and hepatocellular carcinoma (HCC),1416
as well as a reduction in mortality from extrahepatic com-
plications.17 Regression of fibrosis and even cirrhosis has
been documented, as has been demonstrated in other liver
diseases when the underlying cause has been con-
trolled.1821 Nevertheless, reduction in risk is still poten-
tially relative rather than absolute, and ongoing surveillance
and intervention may be required in some patients to
reduce complications arising from liver damage that has
already accrued by the time SVR has been attained. Of
greatest concern is the ongoing risk of HCC in patients with
pre-existing advanced fibrosis or cirrhosis. In this article,
the considerations surrounding the care of patients who
have achieved SVR will be discussed, and proposed recom-
mendations will be presented (Table 1).
Assessment of Hepatitis C Virus RNA
After Sustained Virologic Response
12 Weeks After Treatment Has
Been Attained
With the initiation of trials of DAA regimens, initially in
combination with IFN and later without it, the attainment of
SVR 12 weeks after completion of treatment replaced SVR 24
weeks after completion of treatment as the primary end
Table 1.Recommendations for the Care of Patients With Chronic Hepatitis C Virus Infection Who Have Achieved a Sustained
Virologic Response
Description The purpose of this clinical practice update is to define key principles in the care of patients with
chronic HCV infection who have achieved an SVR after completion of treatment with an all-oral
regimen of DAAs.
Methods The recommendations outlined in this expert review are based on available published evidence,
including randomized controlled trials, observational studies, and systematic reviews, and
incorporate expert opinion where applicable.
Best practice advice (BPA) statements BPA 1: SVR should be confirmed by undetectable HCV RNA at 12 wk after completion of an
all-oral DAA treatment regimen.
BPA 2: Routine confirmation of SVR at 48 wk post end of treatment is recommended. Testing for
HCV RNA at 24 wk post treatment should be considered on an individual patient basis.
BPA 3: Routine testing for HCV RNA beyond 48 wk after end of treatment to evaluate for late
virologic relapse is not supported by available evidence; periodic testing for HCV RNA is
recommended for patients with ongoing risk factors for reinfection.
BPA 4: Surveillance for HCC with liver imaging ± serum AFP should be pursued twice annually for
an indefinite duration in all patients with stage 3 fibrosis or liver cirrhosis post-SVR.
BPA 5: Surveillance for HCC is not recommended for patients with stages 02 fibrosis post-SVR.
BPA 6: Intensification of HCC screening frequency in the immediate post-SVR context is not
currently recommended.
BPA 7: Initial endoscopic screening for esophagogastric varices is recommended for all patients
with liver cirrhosis, independent of SVR.
BPA 8: Repeat endoscopic screening should be pursued for cirrhotic patients post-SVR at 23 y
if no varices or small varices were identified on initial screening examination.
BPA 9: If no varices are identified on endoscopy 23 y post-SVR, cessation of further endoscopic
screening can be considered on an individual patient basis if there are no risk factors for
progressive cirrhosis.
BPA 10: Fibrosis assessment post-SVR with noninvasive tools, such as liver elastography, can be
considered on an individual patient basis to assess for interval fibrosis progression or
regression to guide clinical management, although improved fibrosis measurements should
not alter the frequency of HCC surveillance at the present time.
BPA 11: Patients who have achieved SVR should be counseled regarding sources of liver injury,
which can independently contribute to liver fibrosis progression, including alcohol, fatty liver,
and other potential hepatotoxins, and should be evaluated for these and other sources of liver
injury if serum levels of liver enzymes are elevated.
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Npoint, defined as undetectable HCV RNA on a highly sensitive
polymerase chain reaction assay (lower limit of detection
<12 IU/mL). This transition was based on the rarity of
relapse after follow-up week 12, and it helped move the field
ahead by shortening the intervals between successive trials in
development programs.22 It has become apparent that late
relapse beyond this time point is no more common, and
perhaps less so, than it was after IFN-based therapy
(<1%).710,1213,23,24 For example, in a preliminary report of
long-term outcomes in patients treated with ledipasvir/
sofosbuvir, none of 1850 patients relapsed between the 12th
and 24th week of follow-up.24 As a result, the American As-
sociation for the Study of Liver Diseases/Infectious Diseases
Society of America Guidance document25 has suggested that
patients do not require another HCV RNA determination after
SVR12, and can be dismissed from ongoing follow-up if they
had Metavir F0F2 fibrosis before treatment.
Recent data indicate, however, that late relapse can
indeed occur in the absence of de novo reinfection. In a
series of 1054 patients who achieved SVR12 after receiving
a course of paritaprevir/ritonavir/ombitasvir and dasabu-
vir, representing 97% of patients treated in 6 pivotal trials,
5 (0.5%) had subsequent virologic failure, shown by
phylogenetic analysis to be relapse in 4 patients (3 bypost-treatment week 24 and 1 by post-treatment week 48),
and reinfection in 1 patient. All virologic failures occurred in
GT1a patients.13 In another study of 3004 patients receiving
sofosbuvir-containing therapy, mostly without IFN, 3004
patients had SVR 24 weeks after completion of treatment,
and 12 had reappearance of HCV RNA by follow-up week 24.
Seven of the 12 were shown to have reinfection by phylo-
genetic analyses of either full-length or short-fragment
NS5B sequencing, while 5 patients (0.2%) demonstrated
late relapse with the same virus.12 Although the risk of late
relapse appears to be very low, some clinicians may think it
prudent to obtain another HCV RNA assay at follow-up week
24 and/or follow-up week 48 (the latter as recommended in
the European Association for the Study of the Liver Guide-
lines),26 rather than stopping monitoring after SVR12.25
There is no evidence at present that any particular viral
genotype or patient type is more prone to this rare phe-
nomenon. Registries pursuant to several of the pivotal trial
programs are further evaluating this issue, and refinement
of these recommendations may be appropriate at a future
time. It should be noted that, using viral sequencing, relapse
as late as 68 years of follow-up had historically been
described after IFN therapy,27,28 but this has not been
reported after DAA therapy and the extreme rarity of this
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surveillance for viral reappearance years after DAA therapy.Ongoing Surveillance for Hepatocellular
Carcinoma After Sustained Virologic
Response
HCC is strongly associated with established cirrhosis,
occurring in 1%4% of patients with HCV-associated
cirrhosis annually.29 Many studies, including meta-
analyses, have convincingly demonstrated that the risk of
de novo HCC decreases after SVR is attained with IFN-based
regimens.30 In a pooled analysis of 12 studies, encompass-
ing more than 25,000 patients, SVR was associated with a
relative risk of HCC of 0.24 (95% confidence interval [CI],
0.180.31); 1.5% of SVR patients developed SVR compared
with 6.2% of non-SVR patients. In a further meta-analysis of
6 studies including 2649 patients with advanced hepatic
fibrosis, the hazard ratio for development of SVR was 0.23
(95% CI, 0.160.35).31 In a large study of long-term out-
comes in 530 patients after a median follow-up of 8.4 years
in patients with advanced fibrosis, the 10-year cumulative
HCC incidence rate was lower in patients who achieved SVR
(5.1%) vs those without SVR (21.8%).16 Greater than
10-fold reductions in liver-related mortality, liver trans-
plantation, and liver failure were observed in the SVR group.
Notably, baseline factors significantly associated with all-
cause mortality in this study included older age, genotype
3, higher Ishak fibrosis score, diabetes, and severe alcohol
use. In another study of 307 patients, highly significant re-
ductions in cumulative incidence of both liver cancer and
liver-related complications were observed.15 Reduction in
all-cause mortality in patients who achieve SVR has been
observed even in the absence of baseline cirrhosis in a large
US Veterans Affairs database.14
The literature on this issue has not thus far revealed any
finite point beyond which the risk of HCC in patients with a
history of HCV-associated cirrhosis is reduced to the level of
persons without a history of liver disease. Cases of HCC
occurring beyond 5 years after attainment of SVR have been
well documented. In a Japanese study of patients treated
successfully with IFN-based therapy for HCV, the cumulative
risk of HCC continued to rise through 15 years of follow-up.
Among 562 patients with SVR after IFN-based therapy fol-
lowed for a median observation period of 4.8 years (range,
120.5 years), cumulative HCC rates were 3.1%, 10.1%, and
15.9% at 5, 10, and 15 years, respectively, compared with
15.8%, 35.5%, and 42.3% in 351 patients without SVR.
Significant risk factors for HCC in this study included
fibrosis stage F2F4, age at IFN start 50 years and older,
ethanol consumption 30 g/d and baseline serum a-feto-
protein (AFP) 8 ng/mL.32 In another Japanese study, the
cumulative incidence of HCC among 1094 patients with SVR
after IFN therapy was 3% at a median follow-up of 37
months post-treatment. Cumulative incidence of HCC was
4% at 5 years, 6% at 10 years and 12% after 15 years, with
multivariate analysis revealing significant predictors to be
age 60 years and older, male sex, Metavir F3/4, and AFP10 ng/mL at 1 year after SVR.33 The phenomenon of late
HCC >5 years after SVR has been well documented in the
Western literature as well, with no convincing evidence of
geographic variability in incidence.16,34 In a large US Vet-
erans Affairs study of 10,817 patients who achieved SVR,
with a cumulative rate of HCC after SVR in patients with
cirrhosis of 1.39% per year, significant risk factors in
multivariate analysis included cure after age 55 years, dia-
betes, genotype 3, alcohol use, and Hispanic ethnicity.34
The ongoing risk of HCC in patients with pre-existing
cirrhosis, although lower compared with untreated or un-
successfully treated patients, has led to a widespread
consensus that continued surveillance for HCC is warranted
regardless of other risk factors. Although data from ran-
domized trials are limited, the available evidence and clin-
ical experience overwhelmingly suggest that surveillance is
associated with decreased mortality from HCC,35 and should
occur at 6-month intervals in all cirrhotic patients with or
without SVR. Standard guidelines currently consider AFP
determinations to be adjunctive to imaging or even
optional36; additional studies to determine the value of AFP
in post-SVR surveillance would be of interest.
Ultrasound is the recommended imaging modality for
hepatoma surveillance in both the American Association for
the Study of Liver Diseases Guidelines for HCC, and the
American Association for the Study of Liver Diseases/
Infectious Diseases Society of America HCV guidance docu-
ment.26,36 This recommendation is based on considerations
of cost-effectiveness and the historical use of ultrasound in
studies that have shown an impact on outcomes of early
detection of HCC. However, both computed tomography and
magnetic resonance imaging (MRI) compare favorably to
ultrasound with regard to sensitivity for small HCCs,
particularly in cirrhotic patients.37 In addition, obesity and
overlying bowel gas can impair the accuracy of ultrasound,
and it is not uncommon to receive a radiologic report con-
taining a recommendation to pursue an alternate imaging
modality, leaving the clinician and patient in a potentially
vulnerable position if the recommended imaging studies
are not pursued. Patient-centered approaches are needed
to balance the benefits and risks of contrast-enhanced cross-
sectional imaging studies, such as triphasic computed
tomography scan or MRI, which should be considered
carefully, especially in patients with obesity, “indetermi-
nate” lesions, or those for whom liver ultrasound provides
inadequate visualization of the liver parenchyma. Despite its
greater cost than computed tomography, MRI has the
advantage of avoiding exposure to ionizing radiation. Stra-
tegies such as alternating MRI and liver ultrasound are
commonly used in clinical practice, although they require
further evidence to be incorporated into formal guideline
recommendations. Many radiologists recommend the
routine use of gadoxeate (Eovist; Bayer, Whippany, NJ)
rather than gadolinium contrast for HCC screening with MRI
because of the superior enhancement of liver parenchyma
with the former in patients with cirrhosis.38
Although the risk of HCV-associated HCC is highest in
patients with cirrhosis, HCC may also occur in patients with
bridging fibrosis.39 In some cases, this may be attributable
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cirrhosis after F3 fibrosis was present initially.40 Based on
available evidence for the risk of HCC in this group, HCC
surveillance recommendations for patients with cirrhosis
(liver ultrasound with or without AFP twice per year) have
been applied to patients with F3 fibrosis25,26; the authors
concur with this recommendation.AG
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Sustained Virologic Response Exclusive
to Patients With Advanced Fibrosis
and Cirrhosis?
In determining whether a patient needs post-SVR HCC
screening, the distinction between “moderate” fibrosis (eg,
Metavir F2) and “advanced” fibrosis (F3/4) may not be
easily defined. In addition, it remains possible that even
patients with mild or moderate fibrosis might, on rare
occasion, develop HCC. This suggestion has emerged most
strongly from a large series of patients with SVR after IFN
therapy in Japan. In the study by Yamashita et al,32 42% of
patients who developed HCC among a cohort of 562 SVR
patients followed for a median of 4.8 years post-SVR had F2
fibrosis on liver biopsy. Ikeda et al41 reported that 12 of 706
(1.7%) of patients with F1/2 developed HCC with an inci-
dence of 0.270.47/100 person-years, and 10 of 267
(3.7%) patients with F3/4 with an incidence of 0.621.31
person-years. A third series similarly reported patients with
F0F2 developing HCC, albeit at a much lower rate after
1020 years than patients with F3/4.33 It is unclear from
these reports whether concomitant liver disease (eg,
nonalcoholic steatohepatitis, alcoholic liver disease) could
have caused progressive liver fibrosis after SVR had been
attained.
Far fewer patients with mild to moderate fibrosis and
post-SVR HCC have been reported from the United States
or Europe. In one study, 5 patients who were non-cirrhotic
at SVR subsequently developed HCC (2 with F2 fibrosis, 1
with F2F3 fibrosis, 2 with F3 fibrosis) although one had
evidence for cirrhosis at the time of HCC; HCC diagnoses
occurred within 27 months post-SVR in all cases except
one (68 months).42 In another report of 5 patients who
developed HCC at 37 years post-treatment, 3 did not
have cirrhosis at baseline (1 with F0 fibrosis, 1 with F2
fibrosis, 1 with F3 fibrosis, 2 with cirrhosis); of note, the
patient with F3 at baseline had F2 fibrosis at the time of
HCC diagnosis 5 years post-SVR.43 In the large Veterans
Affairs study by El-Serag et al,34 42 of 100 cases of HCC
post-SVR occurred in non-cirrhotic patients, 11 of whom
were characterized as having low aspartate aminotrans-
ferase to platelet ratio index scores, suggestive of F0F2
fibrosis.
Based on the available evidence, routine screening for
HCC in patients with F0F2 fibrosis is not recommended
after SVR, although some clinicians might choose to obtain
a final ultrasound during the year after SVR following DAA
therapy. Should additional data from “real-world” cohorts
confirm the emergence of late HCC in F0F2 patientspost-SVR, screening recommendations will require
reconsideration.
Can Hepatocellular Carcinoma
Surveillance Ever Be Discontinued?
Lifelong surveillance for HCC among patients with
advanced fibrosis and cirrhosis entails substantial psycho-
logical and economic implications, as well as investments of
time for both patients and clinicians. As evidence continues
to accumulate that fibrosis regression can occur in many
patients who achieve an SVR,1821 it is conceivable that the
risk of HCC could eventually decline to a point at which
surveillance becomes unnecessary.
Unfortunately, there is relatively limited evidence sup-
porting a correlation between measurable regression of
cirrhosis as determined histologically and reduction of HCC
risk. Mallet et al44 studied 96 patients with Child-Pugh A
cirrhosis, of whom 39 (41%) had SVR after IFN-based
therapy. Follow-up liver biopsies were obtained a median
of 17 months after treatment, and patients were followed
for a median of 118 months. Eighteen (18%) experienced
regression from F4 to F0F2, of whom 17 had SVR and the
remaining patient had persistently normal alanine amino-
transferase. Ten-year survival was 100% in those with
cirrhosis regression and 74% in those without regression.
Of the 57 patients without SVR, 14 (23%) developed HCC
compared with 3 (9%) of those with SVR. However, of the
18 patients with regression of cirrhosis on biopsy, including
one who failed to have SVR, none developed HCC. In a more
recent study in 97 SVR patients with paired liver biopsies,
the stage of liver fibrosis regressed in 44 patients (45%)
and progressed in only 6 patients (6%), at a mean of 5.8
years after treatment. HCC was significantly more frequent
in patients with progressive fibrosis than for those in whom
fibrosis regressed or was stable (cumulative incidence 33%
vs 4% at 5 years; P < .05).19
Suggestive as these studies are, post-SVR liver biopsies
are not routinely performed and are not clinically practical,
and it is unlikely that data derived from serial post-SVR liver
biopsies will be sufficiently robust to establish whether
discontinuation of HCC surveillance can be recommended in
patients who demonstrate fibrosis regression. As such,
future longitudinal studies utilizing noninvasive markers or
imaging will likely be utilized to demonstrate long-term
changes in liver fibrosis post-SVR and their potential asso-
ciation with HCC risk. Liver stiffness measurements, most
commonly performed by transient elastography (TE) or
other shear wavebased techniques, have assumed an
increasingly prominent role in HCV management. Short-
term improvement in elastography scores during antiviral
therapy appear to correlate with resolution of inflammation,
declining transiently even in IFN nonresponders, rather
than confirming true fibrosis regression.45 Beyond end of
treatment, further improvement in liver fibrosis has been
reported to occur through follow-up week 24 only in
cirrhotic and non-cirrhotic patients who achieve SVR but
not in nonresponders, in whom stiffness scores increase
post-treatment.4547 One of the few studies to evaluate
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changes to patients receiving IFN from baseline to follow-up
week 24. Sixty percent of patients with liver stiffness-
defined cirrhosis before treatment had liver stiffness scores
>12.5 kPa at SVR24. In this study, there was only a statis-
tically insignificant degree of additional improvement
beyond SVR24.48 In another study of patients with estab-
lished cirrhosis (mean TE liver stiffness measurement 32.5
kPa at baseline) who received interferon-free treatment,
liver stiffness improved between baseline [median (range),
32.5 (9.1–75) kPa] and end of treatment [median (range),
21.3 (6.7–73.5) kPa; (P <. 0001)], and between baseline and
follow-up week 24 [median (range), 21.2 (5.4–70) kPa;
(P <. 0001)]. The authors suggested that most of the
reduction in stiffness scores during the time period of the
study was related to reduced necroinflammation, and that
further studies are needed to evaluate longer term changes
that may reflect regression of severe fibrosis.49
The degree of long-term improvement in liver stiffness
beyond 612 months after end of treatment requires
further clarification. Tachi et al50 correlated acoustic radial
force impulse elastography with liver biopsy findings after a
mean of 5.9 years after treatment and demonstrated a high
degree of accuracy for advanced fibrosis or cirrhosis. Pa-
tients with F0F3 fibrosis at baseline had more improve-
ment in fibrosis after “long-term” than “short-term” SVR, but
patients with F4 did not.
A cautionary note regarding elastography was sounded
by D’Ambrosio et al,51 who studied 33 cirrhotic patients
with SVR after IFN-based therapy. Of 20 patients with
cirrhosis regression on biopsy, 19 (95%) had TE scores <12
kPa; of 13 with persistent cirrhosis, TE scores were <12 kPa
in 5 (38%), conferring on elastography 61% sensitivity and
95% specificity for diagnosing F4 fibrosis after SVR. Rein-
forcing this cautionary theme, Sultanik et al52 reported that
in a cohort of 341 patients with confirmed HCV cirrhosis, 45
(13%) of whom achieved SVR, liver stiffness measurements
by TE were <12.5 kPa in three-fourths of those with SVR.
Utilizing a threshold of 12.5 kPa, the area under the receiver
operating characteristic curve was 0.66 for HCC in patients
with SVR. Of 4 patients with HCC, 2 of 4 had elastography
scores <12 kPa post-SVR. Based on their cumulative data,
the authors cautioned against performing liver stiffness
measurements to follow regression of fibrosis or cirrhosis.52
A study from Taiwan of 278 patients with SVR with a me-
dian follow-up period of 7.6 years, comprised of both non-
cirrhotic and cirrhotic patients, showed a significantly
greater risk of HCC with TE score >12 kPa. However, HCC
also occurred with post-SVR scores <12 kPa, including pa-
tients with pretreatment scores either > or <12 kPa.53 At
present, there is no reliable elastography score below which
clinicians can confirm an absence of HCC risk with sufficient
confidence to warrant discontinuation of surveillance.
The same conclusion can be derived from available
studies on noninvasive blood or serum markers that assess
fibrosis. Such markers often improve after SVR,54,55 and
have correlated with risk of HCC in some studies,56
including a study in which the Forns index, but not
FIB-4 index or aspartate aminotransferase to platelet ratioindex, at follow-up week 24 correlated with long-term HCC
risk. In a particularly long-term follow-up study spanning a
10-year period, FIB-4 index and aspartate aminotransferase
to platelet ratio index scores declined substantially in pa-
tients with SVR and were significantly lower than in un-
treated patients or those with treatment failure, but no
correlations with HCC were drawn.57 In addition, noninva-
sive blood markers have recently demonstrated poor cor-
relation with post-SVR liver biopsy findings.58 Large
databases will eventually address the question of whether
there is an “inflection point” below which improved fibrosis
as measured by elastography scores and/or other nonin-
vasive methods are associated with negligible risks of HCC
that obviate the need for ongoing screening. However, for
the foreseeable future, twice yearly hepatic imaging for
patients with advanced fibrosis and cirrhosis before treat-
ment should be continued indefinitely after SVR.How Should Screening for, and
Management of, Varices Be Affected by
Sustained Virologic Response?
Increasing evidence points to the capacity for SVR to
result in resolution or reduction of portal hypertension,
especially in patients with Child-Pugh A cirrhosis, laying a
foundation for a favorable change in the natural history of
esophageal varices after SVR.59,60 Clinical studies have
indeed provided reassurance that the risk of variceal
bleeding is low after attainment of SVR with IFN-based
therapy.29,40,6163 Bruno et al64 studied 218 patients with
cirrhosis who lacked varices at baseline. The patients un-
derwent endoscopic surveillance every 3 years and had a
median follow-up of 11 years. Of 34 patients with SVR, none
(0%) developed de novo varices. In contrast, varices
developed in 45 of 115 (39%) of nonresponders and 22 of
69 (32%) of untreated patients. Of 4 patients with mea-
surement of hepatic venous pressure gradient, all 4 expe-
rienced a decrease in hepatic venous pressure gradient to
<10 mmHg. In another study of 127 patients with Child-
Pugh A cirrhosis receiving IFN therapy, 62 attained SVR
and 65 did not.65 Fifty-seven of 62 SVR patients followed for
a median of 68 months had no varices at baseline, and only
2 of 57 (3%) developed de novo varices. Of 5 patients with
small varices at baseline, progression of variceal size
occurred in 1 (20%). In contrast, 8 of 53 (15%) of patients
who failed IFN therapy with no varices at baseline devel-
oped de novo varices after a median follow-up of 57 months,
while 2 of 12 (16%) with small varices at baseline had
progression. In the study by Mallet et al44 of 96 patients
with Childs A cirrhosis treated with IFN, of whom 39 had
SVR, and 18 of whom had regression of cirrhosis on follow-
up liver biopsies, 6 of 57 (9.8%) without SVR experienced
variceal bleeding vs one of 39 (2.9%) with SVR. Of the 78
patients without regression of cirrhosis, 7 (9%) without
regression of cirrhosis had variceal bleeding compared with
none of 18 (0%) with such regression.
A somewhat different picture emerged from a study by
Di Marco et al,54 which stratified a prospectively studied
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218 with stage 1 disease and 226 with stage 2 disease. The
patients had received IFN and ribavirin with a median
follow-up of 7.6 years (range, 112.6 years). The distinction
between the 2 stages was based on the absence of varices
(stage 1) or the presence of small varices (stage 2) at
baseline. Patients with stage 1 disease and SVR were less
likely to develop esophageal varices than stage 1 patients
without an SVR (hazard ratio, 0.23; 95% CI, 0.110.48;
P < .001). In contrast, SVR was not associated with a lower
frequency of development of further varices in the stage 2
patients (hazard ratio, 1.58; 95% CI, 0.331.03). SVR
reduced risk of decompensation, HCC, and death regardless
of whether the patients had esophageal varices.
Based on the available literature, a proposed practical
approach to the issue of prophylaxis of variceal bleeding is
as follows: (1) no varices on prior screening examination:
follow-up endoscopy after 23 years and no further
screening if varices are not found and there is no evidence
of another progressive liver disease; (2) small varices on
prior screening examination, no treatment considered
necessary: follow-up endoscopy after 23 years, no further
screening if varices unchanged or smaller, otherwise treat
and follow-up as considered necessary; (3) varices on prior
screening treated with primary prophylaxis with b-blockers
and/or band ligation: repeat after 612 months, continue
treatment if varices unchanged and repeat after 12 years,
consider discontinuation of treatment if varices are repro-
ducibly considered sufficiently small to be considered low
risk; (4) for decompensated patients or patients with a
history of variceal bleeding: continue surveillance and/or
treatment as already instituted. Although updated guide-
lines of the Baveno VI Consensus Workshop support risk
stratification based on TE cutoff of <20 kPa and platelet
count >150,000/mL to identify patients who are at low risk
for clinically significant esophageal varices, and therefore
may not require screening endoscopy, such data in patients
post-SVR are not yet available and therefore application of
these cutoffs in patients after SVR should be approached
with caution and on an individual-patient basis.66AG
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for Regression of Advanced Fibrosis
or Cirrhosis?
Patients who have attained SVR are frequently eager to
know whether pretreatment liver fibrosis can be reversed,
independent of HCC risk. In addition to the issue of whether
HCC screening can eventually be discontinued based on
noninvasive parameters post-SVR, one can envision other
potential roles for ongoing assessment of fibrosis in patients
with advanced liver disease, including addressing patients’
often expressed and understandable desire for information
about improvement in their underlying liver condition,
modulation of surveillance or management of gastroesoph-
ageal varices, the use or dosing of medications metabolized
by the liver, guidance regarding alcohol consumption, and
assessment of patient candidacy for major surgery.Although we anticipate that noninvasive post-SVR
fibrosis assessment may be attractive for many patients
post-treatment, the available evidence does not support a
broad recommendation for routine post-SVR fibrosis testing.
As is the case for HCC surveillance, this may change as new
data emerge from large longitudinal observational database
analyses addressing this issue. For the present, decisions
about noninvasive assessment of fibrosis may be individu-
alized according to clinicians’ judgment and/or patient
preference, but the limitations inherent in the accuracy,
predictive value, and applicability of the information ac-
quired should be discussed.67
Recurrent Hepatocellular Carcinoma
After Sustained Virologic Response
Two studies that have garnered significant attention in
early 2016 suggested unexpectedly high rates of recurrent
HCC in patients treated successfully with DAA regimens
after their tumors had been treated by various methods
other than transplantation. In one study, 9 of 285 patients
(3%) without a history of HCC were diagnosed with a de
novo tumor within 24 weeks after all-oral DAA treatment,
whereas 17 of 59 patients (29%) with prior HCC developed
recurrent HCC post-DAA treatment68; advanced cirrhosis
represented a predictor of recurrent HCC on multivariate
analysis. A second study demonstrated similar findings: 16
of 58 patients (28%) with previously treated HCC devel-
oped recurrent HCC shortly after completion of DAA
therapy.69 It has been speculated that SVR results in down-
regulation of cytokines, including endogenous IFN, that
have anti-tumor effects, thereby creating a more “permis-
sive state” for re-emergence of latent malignant cells. In
contrast, Pol et al70 studied 3 separate ANRS cohorts from
large French multicenter studies of cirrhotic patients, and
found no evidence of a significant increase in HCC inci-
dence relative to comparator populations in any of the 3
groups. The authors suggested that their patient pop-
ulations had undergone treatment modalities with a
greater potential for cure, eg, percutaneous ablation,
resection, or transplantation, whereas the study by Reig
et al69 included patients who had undergone chemo-
embolization, which is likelier to be followed by tumor
recurrence. Similarly, an Italian study has suggested a
reduction in recurrence of HCC previously treated by
ablation or curative resection of early-stage liver cancer
whether patients attained SVR after taking IFN-containing
or IFN-free regimens.71
Although the issue of recurrent HCC after SVR requires
further study, at present there is insufficient evidence to
warrant a change in surveillance strategy for such patients,
nor is there sufficient evidence to suggest that DAA therapy
should be withheld in patients who have undergone
locoregional therapy for HCC previously. Some clinicians
might choose to consider intensification of imaging fre-
quency to every 3 months for a year after completion of HCV
treatment, perhaps depending on the time elapsed since
treatment of HCC and the level of confidence that the tumor
had been ablated.
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The high prevalence of HCV infection in intravenous
drug users has aroused intense interest in targeting this
population for treatment with DAA therapy. Even in the IFN
era, when many clinicians were reluctant to treat such pa-
tients, centers with expertise in the management of these
patients had demonstrated good results with IFN therapy.72
A recent study confirmed that treatment of HCV with gra-
zoprevir/elbasvir is feasible and associated with high SVR
(97%) in patients treated within addiction treatment cen-
ters, many of whom were documented to have used illicit
drugs actively during their HCV treatment.73 However,
confirmed reinfection on population sequencing and
phylogenetic analysis was identified in 6 of 301 patients at
24 weeks post-treatment for an incidence of 4.6 reinfections
per 100 person-years (95% CI, 1.710.0). A long-term
follow-up study of 161 Norwegian patients with HCV ge-
notypes 2 and 3 who attained SVR after interferon-based
therapy in the NORTH-C trial revealed persistent reinfection
in 10 of 94 (11%) with a history of injection drug use
(incidence of 1.7 reinfections per 100 person-years, 95% CI,
0.8–3.1), and 10 of 37 (27%) who relapsed to injection drug
use after treatment (incidence of 4.9 reinfections per 100
person-years; 95% CI, 2.38.9).74 Although reinfection is an
acknowledged risk in this population, the pendulum has
swung toward a high level of advocacy for treatment of
these patients,75,76 both to mitigate their own HCV-related
risks and to reduce transmission in the community. Pa-
tients at risk of reinfection should be monitored by HCV
RNA testing periodically for as long as their risks of expo-
sure are believed to be ongoing, and referred to addiction
management programs, which promote clean needle ex-
change and relapse prevention.
Lifestyle Measures
Although many patients who achieve SVR have a favor-
able clinical course, which might include regression of liver
fibrosis, some patients may experience fibrosis progression,
hepatic decompensation, and/or HCC, with HCC the domi-
nant persistent risk in SVR patients in the absence of
concomitant liver disease. Long-term observational data
addressing liver-related outcomes in patients post-SVR with
oral DAA regimens are lacking. Available data in patients
undergoing IFN-based therapy suggest that individuals who
achieve SVR may continue to experience a higher mortality
rate than the general population,77,78 even among non-
cirrhotic patients who achieve SVR, with a significant
contribution in the latter group from drug-related causes.79
As such, although most excess liver-related outcomes may
be seen in patients with advanced liver fibrosis or cirrhosis
due to persistent risk of liver cancer, all patients achieving
SVR should undergo evaluation for modifiable risk factors
for liver injury, such as alcohol, drug use, fatty liver, and
diabetes mellitus. The impact of alcohol consumption on
liver fibrosis progression and HCC risk in the context of
ongoing chronic hepatitis C infection is well documented,
and even nonhazardous or low to moderate alcohol intake
is associated with an increased risk of liver-relatedoutcomes.80,81 Based on limited data in patients with
eradication of HCV post-SVR, alcohol persists as a risk factor
for all-cause mortality.77 No safe limit for alcohol con-
sumption has been established post-SVR and, therefore,
avoidance of significant alcohol intake should be recom-
mended for all patients, and complete abstinence is prudent
in patients with advanced liver fibrosis or cirrhosis. Dia-
betes and fatty liver are commonly present in patients with
chronic hepatitis C and can develop de novo or persist long-
term as risk factors for liver fibrosis progression and HCC
post-SVR. Diabetes has been confirmed to represent an
important risk factor for HCC in patients with chronic HCV
infection, and appears to remain a risk factor for cirrhosis-
related complications, including HCC post-SVR,34,82,83 as
well as HCC risk in non-cirrhotic patients.84 Fatty liver has
been independently demonstrated to represent a possible
risk factor for liver fibrosis progression85 and HCC86 in
patients who have achieved SVR after antiviral therapy.
Until more data become available to provide evidence-based
recommendations for addressing diabetes and fatty liver in
patients post-SVR, patients at risk or with a known diag-
nosis should be advised of the risk of liver-related compli-
cations, and continue disease-specific management to
optimize weight loss and glycemic control.Conclusions
With the marked increase in number of patients who
achieve SVR with present DAA regimens for hepatitis C,
there is a need to promote a broad-based understanding
among clinicians regarding which patients can be dis-
charged from further HCV-related care, the criteria that
define a need for ongoing management, and the elements
and duration of that management. We have herein proposed
guidelines for management of the post-SVR patient repre-
senting a synthesis of the latest available evidence with
expert opinion. Most of the published evidence and experi-
ence about long-term outcomes after SVR are derived from
studies of IFN-based therapy. It is appropriate at present to
formulate recommendations based on that experience, but
we expect and encourage large long-term studies of out-
comes after IFN-free DAA therapy, which will further refine
our concepts of appropriate management and, like the
guidelines governing antiviral treatment itself, should lead
to dynamic reassessment of the best practices for manage-
ment of patients post-SVR in the years ahead.References
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